Equities Research Analysts’ Updated EPS Estimates for March 27th (AIRJ, ALUR, ATRC, AVON, BACHY, BCAX, BVC, CAN, CAPD, CBG)

Equities Research Analysts’ updated eps estimates for Thursday, March 27th:

Montana Technologies (NASDAQ:AIRJ) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $12.00 price target on the stock.

Allurion Technologies (NYSE:ALUR) had its neutral rating reaffirmed by analysts at Chardan Capital. They currently have a $2.50 price target on the stock.

AtriCure (NASDAQ:ATRC) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $51.00 price target on the stock.

Avon Protection (LON:AVON) had its hold rating reaffirmed by analysts at Shore Capital.

Bank of China (OTCMKTS:BACHY) had its neutral rating reaffirmed by analysts at Bank of America Co..

Bicara Therapeutics (NASDAQ:BCAX) had its outperform rating reiterated by analysts at Wedbush. They currently have a $31.00 price target on the stock.

BATM Advanced Communications (LON:BVC) had its house stock rating reissued by analysts at Shore Capital.

Canaan (NASDAQ:CAN) had its buy rating reissued by analysts at Rosenblatt Securities. They currently have a $8.00 target price on the stock.

Canaan (NASDAQ:CAN) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $3.00 target price on the stock.

Capital (LON:CAPD) had its hold rating reaffirmed by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a GBX 60 ($0.77) price target on the stock.

Close Brothers Group (LON:CBG) had its outperform rating reaffirmed by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a GBX 430 ($5.54) price target on the stock.

Chewy (NYSE:CHWY) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $39.00 target price on the stock.

Chewy (NYSE:CHWY) had its hold rating reissued by analysts at Needham & Company LLC.

Chewy (NYSE:CHWY) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $42.00 price target on the stock.

Cellebrite DI (NASDAQ:CLBT) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $28.00 target price on the stock.

CollPlant Biotechnologies (NASDAQ:CLGN) had its buy rating reiterated by analysts at D. Boral Capital. D. Boral Capital currently has a $14.00 target price on the stock.

Capricorn Energy (LON:CNE) had its buy rating reissued by analysts at Shore Capital.

Canadian Natural Resources (NYSE:CNQ) (TSE:CNQ) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $63.00 price target on the stock.

Vita Coco (NASDAQ:COCO) had its equal weight rating reiterated by analysts at Stephens. The firm currently has a $32.00 target price on the stock.

Coursera (NYSE:COUR) had its underperform rating reissued by analysts at Bank of America Co.. Bank of America Co. currently has a $7.00 price target on the stock.

Coya Therapeutics (NASDAQ:COYA) had its buy rating reissued by analysts at D. Boral Capital. The firm currently has a $18.00 price target on the stock.

California Resources (NYSE:CRC) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a $68.00 target price on the stock.

Cintas (NASDAQ:CTAS) had its sector perform rating reiterated by analysts at Royal Bank of Canada. They currently have a $215.00 target price on the stock.

Cantaloupe (NASDAQ:CTLP) had its outperform rating reissued by analysts at Barrington Research. The firm currently has a $14.00 target price on the stock.

Cognizant Technology Solutions (NASDAQ:CTSH) had its hold rating reaffirmed by analysts at Needham & Company LLC.

Ecora Resources (LON:ECOR) had its buy rating reaffirmed by analysts at Berenberg Bank. The firm currently has a GBX 130 ($1.67) target price on the stock.

Exelixis (NASDAQ:EXEL) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $40.00 target price on the stock.

Helmerich & Payne (NYSE:HP) had its underweight rating reiterated by analysts at Morgan Stanley. They currently have a $27.00 target price on the stock.

Huron Consulting Group (NASDAQ:HURN) had its outperform rating reiterated by analysts at Barrington Research. They currently have a $167.00 price target on the stock.

Leap Therapeutics (NASDAQ:LPTX) had its neutral rating reaffirmed by analysts at HC Wainwright.

Nkarta (NASDAQ:NKTX) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $11.00 target price on the stock.

Nkarta (NASDAQ:NKTX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $18.00 price target on the stock.

NEXT (LON:NXT) had its buy rating reiterated by analysts at Shore Capital.

REX American Resources (NYSE:REX) had its buy rating reiterated by analysts at Truist Financial Co.. They currently have a $50.00 price target on the stock, down from their previous price target of $55.00.

Taboola.com (NASDAQ:TBLA) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $4.00 target price on the stock.

Taboola.com (NASDAQ:TBLA) had its buy rating reiterated by analysts at Benchmark Co.. They currently have a $4.50 target price on the stock.

T-Mobile US (NASDAQ:TMUS) had its buy rating reaffirmed by analysts at Benchmark Co.. The firm currently has a $275.00 price target on the stock.

Tesla (NASDAQ:TSLA) had its outperform rating reiterated by analysts at Wedbush. Wedbush currently has a $550.00 price target on the stock.

Usio (NASDAQ:USIO) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $4.00 price target on the stock.

VF (NYSE:VFC) had its neutral rating reiterated by analysts at Piper Sandler. Piper Sandler currently has a $18.00 price target on the stock.

X4 Pharmaceuticals (NASDAQ:XFOR) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $1.50 target price on the stock.

Zai Lab (NASDAQ:ZLAB) had its overweight rating reissued by analysts at Cantor Fitzgerald.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $10.00 price target on the stock.